The CRASH-2 trial evaluated the effects of early administration of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant bleeding. The study was conducted in 274 hospitals across 40 countries and involved 20,211 adult trauma patients. Patients were randomly assigned within 8 hours of injury to receive either tranexamic acid (loading dose of 1 g over 10 minutes followed by an infusion of 1 g over 8 hours) or a matching placebo. The primary outcome was death within 4 weeks of injury, categorized by cause. The results showed a significant reduction in all-cause mortality (1463 deaths in the tranexamic acid group vs 1613 in the placebo group; relative risk [RR] 0.91, 95% CI 0.85-0.97; p=0.0035) and deaths due to bleeding (489 vs 574; RR 0.85, 95% CI 0.76-0.96; p=0.0077). There was no significant difference in vascular occlusive events (168 vs 201; p=0.14) or blood product transfusions (5067 vs 5160; p=0.34). The study concluded that tranexamic acid safely reduced the risk of death in bleeding trauma patients and should be considered for use in this patient population.The CRASH-2 trial evaluated the effects of early administration of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant bleeding. The study was conducted in 274 hospitals across 40 countries and involved 20,211 adult trauma patients. Patients were randomly assigned within 8 hours of injury to receive either tranexamic acid (loading dose of 1 g over 10 minutes followed by an infusion of 1 g over 8 hours) or a matching placebo. The primary outcome was death within 4 weeks of injury, categorized by cause. The results showed a significant reduction in all-cause mortality (1463 deaths in the tranexamic acid group vs 1613 in the placebo group; relative risk [RR] 0.91, 95% CI 0.85-0.97; p=0.0035) and deaths due to bleeding (489 vs 574; RR 0.85, 95% CI 0.76-0.96; p=0.0077). There was no significant difference in vascular occlusive events (168 vs 201; p=0.14) or blood product transfusions (5067 vs 5160; p=0.34). The study concluded that tranexamic acid safely reduced the risk of death in bleeding trauma patients and should be considered for use in this patient population.